Photo by nhiamoua from unsplash
The Lung Cancer Mutation Consortium (LCMC) was launched as a cross-institutional effort to prospectively follow non-small cell lung cancer (NSCLC) patients across sixteen centers in the US, with a focus… Click to show full abstract
The Lung Cancer Mutation Consortium (LCMC) was launched as a cross-institutional effort to prospectively follow non-small cell lung cancer (NSCLC) patients across sixteen centers in the US, with a focus on genomic mutation profiles, in an effort to improve the selection of effective therapeutic courses (1).
Keywords:
lung;
mutational profiling;
prioritizing mutational;
profiling targeted;
therapy lung;
targeted therapy
Journal Title: Journal of thoracic disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of thoracic disease
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!